{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:57:11Z","timestamp":1648774631595},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s00063-018-0518-7","type":"journal-article","created":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T12:47:21Z","timestamp":1544705241000},"page":"198-204","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CAR, CRS und Neurotoxizit\u00e4t: schwere Komplikationen der Immuntherapie"],"prefix":"10.1007","volume":"115","author":[{"given":"J.","family":"Prinz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"d\u2019Hargues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"G\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Shimabukuro-Vornhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kochanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"B\u00f6ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"518_CR1","volume-title":"EMA: CAR-T-Zelltherapie demn\u00e4chst auch in Europa","author":"Paul Ehrlich Institut","year":"2018","unstructured":"Paul Ehrlich Institut (2018) EMA: CAR-T-Zelltherapie demn\u00e4chst auch in Europa. \nhttps:\/\/www.pei.de\/DE\/home\/europaeische-kommission-erteilt-zulassung-fuer-car-t-zelltherapeutika.html\n\n. Zugegriffen: 4. Okt. 2018"},{"key":"518_CR2","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.11","volume":"3","author":"CL Bonifant","year":"2016","unstructured":"Bonifant CL, Jackson HJ, Brentjens RJ et al (2016) Toxicity and management in CAR T\u2011cell therapy. Mol Ther Oncolytics 3:16011","journal-title":"Mol Ther Oncolytics"},{"issue":"S1","key":"518_CR3","first-page":"799","volume":"2","author":"P Borchmann","year":"2018","unstructured":"Borchmann P et al (2018) An updated analysis of JULIET, a\u00a0global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B\u2014cell lymphoma. HemaSphere 2(S1):799","journal-title":"HemaSphere"},{"key":"518_CR4","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN (2016) Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 127:3321\u20133330","journal-title":"Blood"},{"key":"518_CR5","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra225","journal-title":"Sci Transl Med"},{"key":"518_CR6","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1158\/1078-0432.CCR-14-1678","volume":"21","author":"A Deisseroth","year":"2015","unstructured":"Deisseroth A, Ko CW, Nie L et\u00a0al (2015) FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease. Clin Cancer Res 21:950\u2013954","journal-title":"Clin Cancer Res"},{"key":"518_CR7","unstructured":"Grady D (2012) In Girl\u2019s Last Hope, Altered Immune Cells Beat Leukemia. \nhttps:\/\/www.nytimes.com\/2012\/12\/10\/health\/a-breakthrough-against-leukemia-using-altered-t-cells.html\n\n. Zugegriffen: 09.12.2018"},{"key":"518_CR8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D et al (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T\u2011cell therapy. Blood 130:2295\u20132306","journal-title":"Blood"},{"key":"518_CR9","unstructured":"https:\/\/www.eortc.be\/services\/doc\/ctc\/ctcae_4.03_2010-06-14_quickreference_5x7.pdf\n\n. Zugegriffen: 09.12.2018"},{"key":"518_CR10","unstructured":"Medienmitteilung Roche: Basel (2017) \nhttps:\/\/www.roche.com\/de\/media\/store\/releases\/med-cor-2017-08-30.htm\n\n. Zugegriffen: 09.12.2018"},{"key":"518_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.coi.2015.01.002","volume":"33","author":"MC Jensen","year":"2015","unstructured":"Jensen MC, Riddell SR (2015) Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 33:9\u201315","journal-title":"Curr Opin Immunol"},{"key":"518_CR12","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","volume":"25","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, Somerville RPT, Lu T et al (2017) Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther 25:2245\u20132253","journal-title":"Mol Ther"},{"key":"518_CR13","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL et\u00a0al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188\u2013195","journal-title":"Blood"},{"key":"518_CR14","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a\u00a0phase 1 dose-escalation trial. Lancet 385:517\u2013528","journal-title":"Lancet"},{"key":"518_CR15","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA et\u00a0al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N\u00a0Engl J Med 371:1507\u20131517","journal-title":"N Engl J Med"},{"key":"518_CR16","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00381-016-3240-x","volume":"32","author":"R Murayi","year":"2016","unstructured":"Murayi R, Chittiboina P (2016) Glucocorticoids in the management of peritumoral brain edema: a\u00a0review of molecular mechanisms. Childs Nerv Syst 32:2293\u20132302","journal-title":"Childs Nerv. Syst."},{"key":"518_CR17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene Ciloleucel CAR T\u2011cell therapy in refractory large B\u2011cell lymphoma. N\u00a0Engl J Med. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"518_CR18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P et al (2018) Chimeric antigen receptor T\u2011cell therapy\u2014assessment and management of toxicities. Nat Rev Clin Oncol 15:47\u201362","journal-title":"Nat Rev Clin Oncol"},{"key":"518_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S1388-9842(01)00137-4","volume":"3","author":"G Plenz","year":"2001","unstructured":"Plenz G, Song ZF, Tjan TD et al (2001) Activation of the cardiac interleukin-6 system in advanced heart failure. Eur J Heart Fail 3:415\u2013421","journal-title":"Eur J Heart Fail"},{"key":"518_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","volume":"11","author":"D Porter","year":"2018","unstructured":"Porter D, Frey N, Wood PA et\u00a0al (2018) Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J\u00a0Hematol Oncol 11:35","journal-title":"J Hematol Oncol"},{"key":"518_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1387905","author":"ZJ Roberts","year":"2017","unstructured":"Roberts ZJ, Better M, Bot A et al (2017) Axicabtagene ciloleucel, a\u00a0first-in-class CAR T cell therapy for aggressive NHL. Leuk Lymphoma. \nhttps:\/\/doi.org\/10.1080\/10428194.2017.1387905","journal-title":"Leuk Lymphoma"},{"key":"518_CR22","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.7150\/ijbs.4989","volume":"8","author":"S Rose-John","year":"2012","unstructured":"Rose-John S (2012) IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8:1237\u20131247","journal-title":"Int J Biol Sci"},{"key":"518_CR23","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-NB2017-126","author":"S Rose","year":"2017","unstructured":"Rose S (2017) First-Ever CAR T\u2011cell Therapy Approved in U.S. Cancer Discov. \nhttps:\/\/doi.org\/10.1158\/2159-8290.CD-NB2017-126","journal-title":"Cancer Discov."},{"key":"518_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1708566","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA et al (2017) Chimeric antigen receptor T cells in refractory B\u2011cell lymphomas. N\u00a0Engl J Med. \nhttps:\/\/doi.org\/10.1056\/nejmoa1708566","journal-title":"N Engl J Med"},{"key":"518_CR25","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.jcyt.2017.04.001","volume":"19","author":"N Singh","year":"2017","unstructured":"Singh N, Hofmann TJ, Gershenson Z et al (2017) Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T\u2011cell function. Cytotherapy 19:867\u2013880","journal-title":"Cytotherapy"},{"key":"518_CR26","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.1056\/NEJMe1714680","volume":"377","author":"E Tran","year":"2017","unstructured":"Tran E, Longo DL, Urba WJ (2017) A milestone for CAR T cells. N\u00a0Engl J Med 377:2593\u20132596","journal-title":"N Engl J Med"},{"key":"518_CR27","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","volume":"8","author":"CJ Turtle","year":"2016","unstructured":"Turtle CJ, Hanafi LA, Berger C et al (2016) Immunotherapy of non-Hodgkin\u2019s lymphoma with a\u00a0defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Sci Transl Med 8:355ra116","journal-title":"Sci Transl Med"},{"key":"518_CR28","unstructured":"Modifiziert nach Sevier Medical. CC BY 3.0; \nhttps:\/\/creativecommons.org\/licenses\/by\/3.0\/deed.de\n\n. \nhttps:\/\/smart.servier.com\/\n\n. Zugegriffen: 23. Nov. 2018"},{"key":"518_CR29","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Riviere I (2016) Clinical manufacturing of CAR T cells: foundation of a\u00a0promising therapy. Mol Ther Oncolytics 3:16015","journal-title":"Mol Ther Oncolytics"},{"key":"518_CR30","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1172\/JCI83871","volume":"125","author":"Y Yang","year":"2015","unstructured":"Yang Y (2015) Cancer immunotherapy: harnessing the immune system to battle cancer. J\u00a0Clin Invest 125:3335\u20133337","journal-title":"J Clin Invest"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-018-0518-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00063-018-0518-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-018-0518-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T19:19:20Z","timestamp":1586200760000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00063-018-0518-7"}},"subtitle":["Was der Intensivmediziner wissen muss"],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["518"],"URL":"https:\/\/doi.org\/10.1007\/s00063-018-0518-7","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"assertion":[{"value":"9 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Prinz, Y.\u00a0d\u2019Hargues, P.\u00a0G\u00f6del, A.\u00a0Shimabukuro-Vornhagen und M.\u00a0Kochanek geben an, dass kein Interessenkonflikt besteht. B.\u00a0B\u00f6ll erhielt Honorare und\/oder Forschungsunterst\u00fctzung von Baxalta, Celgene, MSD, Astellas, Johnson & Johnson, Takeda, und Mundipharma au\u00dferhalb der vorliegenden Arbeit.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}